← boardnext 2039-07
GLPGF
Lakefront Biotherapeutics NVdistress 0/10 · well-funded / low risk$28.080%today-17% from 52w high
Dermatology 1
Lead: Hematological Malignancies
Revenue
pre-revenue
Liquidity
$3030M
Runway
11.8 yrs
Shares 1y
0%
Price & events
-11.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
-11.4%
6M
-1.9%
1Y
+14.4%
2Y
-51.2%
5Y
-71.5%
All
Overview
- Market Cap
- $1.85B
- Volume
- 0
- 52 Week Range
- $28.08 – $34.00
- Total Shares
- 65.90M
- Float Shares
- 40.94M
- % Held by Insiders
- 25.36%
- % Held by Institutions
- 33.68%
- Beta
- 0.12
Pipeline stages · 2 programs
GLPG CAR T-cell therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GLPG3667
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2039-07 Estimated 50% readout ~2039-09-14 | Phase 3 | GLPG CAR T-cell therapy | Hematological Malignancies | — | recruiting |
| 2025-10-13 | Phase 2 | GLPG3667 | Dermatomyositis | 40 | completed |
Catalyst news & presentations · 1
- 2026-08-10earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 65,897,071 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Hematological Malignancies
Recent news
- 2026-07-21Lakefront Biotherapeutics (LKFT) repurchases 98,648 shares in July - Stock Titan
- 2026-07-15Lakefront Biotherapeutics (LKFT) repurchases 108,645 shares at €26.67 - Stock Titan
- 2026-07-14What You Need To Know About The Lakefront Biotherapeutics NV (AMS:LKFT) Analyst Downgrade Today - simplywall.st
- 2026-07-13Lakefront Biotherapeutics director resigns for Sanofi role - Investing.com
- 2026-07-13[6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer) | LKFT SEC Filing - Form 6-K - Stock Titan
- 2026-07-10Lakefront Biotherapeutics (LKFT) Coverage Resumed by Morgan Stan - GuruFocus
- 2026-07-10Lakefront draws Equal Weight rating at Morgan Stanley (LKFT) - Seeking Alpha
- 2026-07-07Lakefront Biotherapeutics (NASDAQ: LKFT) details €2.73M share repurchase activity - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.